Benitec Biopharma (BNTC) vs Clinuvel Pharmaceuticals (CUVL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Clinuvel Pharmaceuticals (CUVL) has outperformed Benitec Biopharma (BNTC) over the past year, losing 29.7% versus a loss of 34.8%. Over five years, CUVL leads with a -80.9% price change compared with -85.3% for BNTC. Benitec Biopharma is the larger company by market cap ($307.8 million vs $281.7 million), about 1.1 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.90%, while Benitec Biopharma does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | CUVL |
|---|---|---|
| Share price | $8.83 | $5.58 |
| Market cap | $307.84M | $281.72M |
| 1-day change | -1.84% | -3.79% |
| YTD return | -33.26% | -31.60% |
| 1-year return | -34.76% | -29.70% |
| 5-year return | -85.27% | -80.95% |
| P/E ratio (TTM) | — | 12.40 |
| EPS (TTM) | $-0.98 | $0.45 |
| Dividend yield | 0.00% | 0.90% |
| Annual dividend | $0.00 | $0.05 |
| 52-week high | $16.76 | $8.92 |
| 52-week low | $8.52 | $5.56 |
| Distance from 52-week high | -47.34% | -37.44% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +175.69% | — |
| Average volume | 152.08K | 12.84K |
| Shares outstanding | 34.88M | 50.49M |
| Employees | 24 | — |
| Sector | Health Care | Miscellaneous |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Benitec Biopharma in Health Care and Clinuvel Pharmaceuticals in Miscellaneous.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
BNTC vs CUVL FAQ
Which is bigger, Benitec Biopharma or Clinuvel Pharmaceuticals?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $307.84M compared with $281.72M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, BNTC or CUVL?
CUVL returned -29.70% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Benitec Biopharma or Clinuvel Pharmaceuticals?
Clinuvel Pharmaceuticals pays a dividend yielding 0.90%, while Benitec Biopharma does not currently pay a regular dividend.
Are Benitec Biopharma and Clinuvel Pharmaceuticals in the same industry?
No. Benitec Biopharma is in the Health Care sector, while Clinuvel Pharmaceuticals is in Miscellaneous.